Challenges in selectivity, specificity and quantitation range of ligand-binding assays: Case studies using a microfluidics platform

Bioanalysis

Volumn 6, Issue 8, 2014, Pages 1049-1057

  Yang, Tong Yuan ^a   Uhlinger, David J ^a   Ayers, Stephen A ^a   O'hara, Denise M ^b   Joyce, Alison P ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN; LIGAND;

ARTICLE; CALIBRATION; COMPARATIVE STUDY; DRUG COMPETITION; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; MICROFLUIDICS; PHARMACODYNAMICS; RECEPTOR BINDING ASSAY; SIGNAL TRANSDUCTION; DEVICES; HUMAN; IMMUNOASSAY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; LIGANDS; MICROFLUIDICS; SENSITIVITY AND SPECIFICITY;

EID: 84901016626     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.60     Document Type: Article

References (12)

1. Wu AH. A selected history and future of immunoassay development and applications in clinical chemistry. Clin. Chim. Acta 369(2), 119-124 (2006
2. Fraley KJ, Abberley L, Hottenstein CS, Ulicne JJ, Citerone DR, Szapacs ME. The Gyrolab immunoassay system: A platform for automated bioanalysis and rapid sample turnaround. Bioanalysis 5(14), 1765-1774 (2013
3. Given AM, Whalen PM, O'Brien PJ, Ray CA. Development and validation of an alpha fetoprotein immunoassay using Gyros technology. J. Pharm. Biomed. Anal. 64-65, 8-15 (2012
4. Liu R, Pillutla R, Desilva B, Zhang YJ. Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs. Bioanalysis 5(14), 1751-1763 (2013
5. Liu XF, Wang X, Weaver RJ et al. Validation of a Gyrolab assay for quantification of rituximab in human serum. J. Pharmacol. Toxicol. Methods 65(3), 107-114 (2012
6. Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, Drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 365(1-2), 38-49 (2011
7. Mora JR, Obenauer-Kutner L, Vimal Patel V. Application of the Gyrolab platform to ligand-binding assays: A user's perspective. Bioanalysis 2(10), 1711-1715 (2010
8. Roman J, Qiu J, Dornadula G, Hamuro L, Bakhtiar R, Verch T. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. J. Pharmacol. Toxicol. Methods 63(3), 227-235 (2011
9. Lee J, Kelley M, King L et al. Bioanalytical approaches to quantify total and free therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
10. Leary BA, Lawrence-Henderson R, Mallozzi C et al. Bioanalytical platform comparison using a generic human IgG PK assay format. J. Immunol. Methods 397(1-2), 28-36 (2013
11. Dudal S, Baltrukonis D, Crisino R et al. Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 16(2), 194-205 (2014
12. Goodman J, Agoram B. Analytical assay platforms for soluble target engagement biomarkers: Old favorites and emerging technologies. Bioanalysis 5(23), 2919-2931 (2013